Yiling Pharmaceutical: Clinical trial approval for the new traditional Chinese medicine Qilong Dingchuan Tablets

2026-03-27 21:11:03

People’s Finance News, March 26: On March 26, Yiling Pharmaceutical (002603) announced that it received a “Drug Clinical Trial Approval Notice” issued and approved by the National Medical Products Administration. The notice approved the company’s development of a clinical trial for the tablet Qilong Dingchuan Pills, for the stable-stage cardiopulmonary qi deficiency and the syndrome of phlegm and blood stasis obstructing the lungs in patients with chronic obstructive pulmonary disease. Qilong Dingchuan Pills are a TCM innovative drug for the treatment of chronic obstructive pulmonary disease, developed based on the theory of pulmonary collateral disease and its syndrome treatment, under the guidance of the theory of collateral disease in traditional Chinese medicine.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes